ABCAM PLC Total Voting Rights (9060B)
04 Febbraio 2020 - 11:49AM
UK Regulatory
TIDMABC
RNS Number : 9060B
ABCAM PLC
04 February 2020
For immediate release 04 February 2020
ABCAM PLC
("Abcam" or "Company")
Total Voting Rights - Voting Rights and Capital
In conformity with the Disclosure Rules and Transparency Rules,
provision 5.6.1, the Company notifies the market of the
following:
The Company's issued share capital consists of 206,073,250
Ordinary Shares of 0.2p each with voting rights. The Company does
not hold any shares in Treasury.
The above figure of 206,073,250 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure and
Transparency Rules.
Date of Notification: 04 February 2020.
For further information please contact:
+ 44 (0) 1223 696
Abcam 000
Marc Perkins, Company Secretary
J.P.Morgan Cazenove - Nominated Adviser & Corporate + 44 (0) 20 7742
Broker 4000
James Mitford / Jonty Edwards
FTI Consulting +44 (0) 20 3727
Ben Atwell / Brett Pollard / Natalie Garland-Collins 1000
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's thirteen locations are in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Company sells to more than 100 countries. Abcam was admitted to AIM
in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRUPUMCPUPUGUC
(END) Dow Jones Newswires
February 04, 2020 05:49 ET (10:49 GMT)
Grafico Azioni Abcam (LSE:ABC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Abcam (LSE:ABC)
Storico
Da Mar 2023 a Mar 2024